KYMR Stock Analysis: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$110.40
-8.95 (-7.50%)
▼
5d:
-3.8%
30d:
+41.12%
90d:
+29.81%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KYMR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: KYMR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $110.40, which is considered slightly high relative to its 30-day fair value range of $84.30 to $115.42.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $105.00, while resistance sits at $120.90. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: KYMR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $123.76 (+12.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $105.00, while resistance sits at $120.90. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: KYMR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $123.76 (+12.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$84.30 -
$115.42
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading below Wall St target ($123.76)
Trading Range Analysis
30-Day Trading Range
$84.30 -
$115.42
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$8.91
(8.1%)
Support & Resistance Levels
Support Level
$105.00
Resistance Level
$120.90
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.40
Wall Street Target
$123.76
(+12.1%)
Revenue Growth (YoY)
55.5%
Share & Embed Analysis
Last updated: July 14, 2026 1:21 AM ET
Data refreshes hourly during market hours. Next update: 2:21 AM
Data refreshes hourly during market hours. Next update: 2:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce Booth
SELL
5900 shares
2026-04-22
Jeremy G Chadwick
SELL
300 shares
2026-04-22
Bruce Booth
SELL
100 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
